Since cell lines containing mutant p53 appear to be more sensitive to statins than p53 wild-type cells [20] theoretically, the benefit of statins in the tripe-negative cohort relative to the non-TN patients could be a least partly due to the considerable greater prevalence of p53 mutations in the former subtype of breast cancer [5]. The gene discussed is TP53; the disease is breast carcinoma.